Naturally improving the natural cytotoxicity of natural killer (NK) cells
| العنوان: | Naturally improving the natural cytotoxicity of natural killer (NK) cells |
|---|---|
| المؤلفون: | Villalba, Martin, Alexia, Catherine, Bellin-Robert, Anais, Fayd'herbe De Maudave, Alexis, Gitenay, Delphine |
| المساهمون: | Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), villalba, martin |
| المصدر: | Frontiers in Immunology Frontiers in Immunology, Frontiers, 2020, 10, pp.3026. ⟨10.3389/fimmu.2019.03026⟩ Frontiers in Immunology, Frontiers, 2020 |
| بيانات النشر: | HAL CCSD, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | [SDV] Life Sciences [q-bio], antibody-dependent cell cytotoxicity (ADCC), [SDV.IMM] Life Sciences [q-bio]/Immunology, CD45RARO, [SDV]Life Sciences [q-bio], [SDV.IMM]Life Sciences [q-bio]/Immunology, autoimmune diseases, NK cells, [SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity, microenvironment, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, ComputingMilieux_MISCELLANEOUS, monoclonal antibodies (mAbs) |
| الوصف: | International audience; The innate lymphocyte lineage natural killer (NK) is now the target of multiple clinical applications, although none has received an agreement from any regulatory agency yet. Transplant of naïve NK cells has not proven efficient enough in the vast majority of clinical trials. Hence, new protocols wish to improve their medical use by producing them from stem cells and/or modifying them by genetic engineering. These techniques have given interesting results but these improvements often hide that natural killers are mainly that: natural. We discuss here different ways to take advantage of NK physiology to improve their clinical activity without the need of additional modifications except for in vitro activation and expansion and allograft in patients. Some of these tactics include combination with monoclonal antibodies (mAb), drugs that change metabolism and engraftment of specific NK subsets with particular activity. Finally, we propose to use specific NK cell subsets found in certain patients that show increase activity against a specific disease, including the use of NK cells derived from patients. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1664-3224 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::66028bc14551fe2d039ccd7316b95689 https://www.hal.inserm.fr/inserm-02711666/file/fimmu-10-03026.pdf |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.dedup.wf.001..66028bc14551fe2d039ccd7316b95689 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|